Cargando…

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study

BACKGROUND: Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare. Thus, we aimed to assess the effect of pioglitazone on primary stroke prevention in Asi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Yi-Chih, Chiu, Lu-Ting, Huang, Hung-Yu, Bau, Da-Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306145/ https://www.ncbi.nlm.nih.gov/pubmed/32563247 http://dx.doi.org/10.1186/s12933-020-01056-x

Ejemplares similares

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
por: Rodríguez, Ángel, et al.
Publicado: (2011)

Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
por: Woo, Min-Hee, et al.
Publicado: (2019)

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
por: Li, Yan-Rong, et al.
Publicado: (2018)

Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study
por: Chen, Yin-Huei, et al.
Publicado: (2017)

Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan
por: Peng, Zi-Yang, et al.
Publicado: (2022)

Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case–control study
por: Ha, Junghee, et al.
Publicado: (2021)

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
por: Liao, Hung-Wei, et al.
Publicado: (2017)

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2009)

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
por: Zou, Cong, et al.
Publicado: (2013)

Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report
por: Suzuki, Hirofumi, et al.
Publicado: (2013)

Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

Association of Diabetic Retinopathy and Diabetic Kidney Disease With All-Cause and Cardiovascular Mortality in a Multiethnic Asian Population
por: Sabanayagam, Charumathi, et al.
Publicado: (2019)

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms
por: Tian, Yuling, et al.
Publicado: (2017)

Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
por: Naka, Katerina K, et al.
Publicado: (2010)

Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2021)

Underweight is a major risk factor for atrial fibrillation in Asian people with type 2 diabetes mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2021)

Metabolic syndrome and concomitant diabetes mellitus are associated with higher risk of cardiovascular comorbidity in patients with primary glomerular diseases: A retrospective observational study
por: Xie, Zhiyong, et al.
Publicado: (2020)

Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement
por: Huang, Jo-Ting, et al.
Publicado: (2022)

Corrigendum: Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
por: Yang, Ming-Chi, et al.
Publicado: (2022)

Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus
por: Yiu, Kai-Hang, et al.
Publicado: (2014)

Low mannose-binding lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic south asians. a prospective cohort study
por: Siezenga, Machiel A, et al.
Publicado: (2011)

How Does Pioglitazone Prevent Progression of Impaired Glucose Tolerance to Diabetes?
por: Genuth, Saul M.
Publicado: (2013)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Using the spring constant method to analyze arterial elasticity in type 2 diabetic patients
por: Wei, Ching-Chuan, et al.
Publicado: (2012)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation
por: Biscetti, Federico, et al.
Publicado: (2009)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

A retrospective cohort study examining secondary prevention post stroke in primary care in an Asian setting
por: Bansal, Vivek, et al.
Publicado: (2021)

Phenotyping diabetic cardiomyopathy in Europeans and South Asians
por: Paiman, Elisabeth H. M., et al.
Publicado: (2019)

A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk
por: Derosa, Giuseppe, et al.
Publicado: (2015)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009)

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
por: Chan, Cheng-Wei, et al.
Publicado: (2018)

Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress
por: Zhao, Chun Ting, et al.
Publicado: (2012)

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study
por: Pintaudi, Basilio, et al.
Publicado: (2021)

Outcomes in a diabetic population of south Asians and whites following hospitalization for acute myocardial infarction: a retrospective cohort study
por: Nijjar, Aman PK, et al.
Publicado: (2010)

Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study
por: Ting, Rose ZW, et al.
Publicado: (2010)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_da1jec65f8kglj1fdu0ormv6uv